Cellzome is a drug discovery company applying its world-class technology to the discovery and development of a pipeline of distinctive, small molecule, therapeutics targeted at inflammatory diseases.
A particular, patented, form of the technology, called Kinobeads™, enables the quantitative analysis of compounds interacting with their kinase targets, in active or inactive confirmations, directly in relevant cells or tissues. Because no use is made of recombinant protein or labelling techniques, the technology offers advantages both in speeding up screening and selectivity profiling, especially for problematic targets, as well as the generation of data of superior physiological relevance.
Cellzome is building value for shareholders by commercializing its technology and assets through: * The development of a pipeline of small molecule pharmaceuticals, initially for inflammatory disease, focused on » kinase targets. * A collaboration with Ortho-McNeil Pharmaceutical and Johnson & Johnson PRD, focused on developing a series of small-molecule γ-secretase modulators for the treatment of » Alzheimer’s Disease, in return for research payments, milestone payments, and royalties on sales. * A large pan-therapeutic » collaboration with Novartis Institutes for Biomedical Research Inc. (NIBRI), discovering new drug targets and leads in a variety of disease areas, in return for research payments and, in certain circumstances, lead compound development options for both companies in exchange for licenses, milestone payments and royalties.
Led by a management team with strong scientific and commercial credentials, and backed by some of the biotech industry’s most experienced investors, Cellzome is intent on developing both organically and through merger or acquisition.
Cellzome is domiciled in the USA and employs about 80 people at its facilities in Cambridge, UK and Heidelberg, Germany.